EvolveImmune Therapeutics

About:

EvolveImmune Therapeutics develops a modular biotherapeutics platform specialized in immuno-oncology.

Website: https://evolveimmune.com

Twitter/X: evolveimmune

Top Investors: Pfizer, Takeda Ventures, Yonjin Venture, Solasta Ventures, Elm Street Ventures

Description:

EvolveImmune Therapeutics develops an immunobiological platform that delivers both sustained immune activation and tumor cell targeting in a single agent. Through integrated signaling, EVs first in category biologics directly target tumor cells and provide potent, tissue-localized amplification of cytokine secretion at the tumor site to maximize tumor killing. The company's biotherapeutics are engineered to overcome the limitations of conventional CD3 bispecific and other immune therapies to offer a better future for our patients in need, by maximizing therapeutic benefit and minimizing toxicity.

Total Funding Amount:

$74.9M

Estimated Revenue Range:

$1M to $10M

Headquarters Location:

Branford, Connecticut, United States

Founded Date:

2020-01-01

Contact Email:

info(AT)evolveimmune.com

Founders:

Charles Fuchs, Sidi Chen, Stephen Bloch

Number of Employees:

11-50

Last Funding Date:

2024-10-29

IPO Status:

Private

Industries:

© 2025 bioDAO.ai